Amplification of 8q is frequently found in gastroesophageal junction (GEJ) cancer. It is usually detected in high-grade, high-stage GEJ adenocarcinomas. Moreover, it has been implicated in tumor progression in other cancer types. In this study, a detailed genomic analysis of 8q was performed on a series of GEJ adenocarcinomas, including 22 primary adenocarcinomas, 13 cell lines and two xenografts, by array comparative genomic hybridization (aCGH) with a whole chromosome 8q contig array. Of the 37 specimens, 21 originated from the esophagus and 16 were derived from the gastric cardia. Commonly overrepresented regions were identified at distal 8q, i.e. 124–125 Mb (8q24.13), at 127–128 Mb (8q24.21), and at 141–142 Mb (8q24.3). From these regions six genes were selected with putative relevance to cancer: ANXA13, MTSS1, FAM84B (alias NSE2), MYC, C8orf17 (alias MOST-1) and PTK2 (alias FAK). In addition, the gene EXT1 was selected since it was found in a specific amplification in cell line SK-GT-5. Quantitative RT-PCR analysis of these seven genes was subsequently performed on a panel of 24 gastroesophageal samples, including 13 cell lines, two xenografts and nine normal stomach controls. Significant overexpression was found for MYC and EXT1 in GEJ adenocarcinoma cell lines and xenografts compared to normal controls. Expression of the genes MTSS1, FAM84B and C8orf17 was found to be significantly decreased in this set of cell lines and xenografts. We conclude that, firstly, there are other genes than MYC involved in the 8q amplification in GEJ cancer. Secondly, the differential expression of these genes contributes to unravel the biology of GEJ adenocarcinomas.

1.
Adam PJ, Boyd R, Tyson KL, Fletcher GC, Stamps A, et al: Comprehensive proteomic analysis of breast cancer cell membranes reveals unique proteins with potential roles in clinical cancer. J Biol Chem 278:6482–6489 (2003).
2.
Ahn J, Ludecke HJ, Lindow S, Horton WA, Lee B, et al: Cloning of the putative tumour suppressor gene for hereditary multiple exostoses (EXT1). Nat Genet 11:137–143 (1995).
3.
Alers JC, Rochat J, Krijtenburg PJ, Hop WC, Kranse R, et al: Identification of genetic markers for prostatic cancer progression. Lab Invest 80:931–942 (2000).
4.
Altorki N, Schwartz GK, Blundell M, Davis BM, Kelsen DP, Albino AP: Characterization of cell lines established from human gastric-esophageal adenocarcinomas. Biologic phenotype and invasion potential. Cancer 72:649–657 (1993).
5.
Botterweck AA, Schouten LJ, Volovics A, Dorant E, van Den Brandt PA: Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 29:645–654 (2000).
6.
Cameron AJ, Ott BJ, Payne WS: The incidence of adenocarcinoma in columnar-lined (Barrett’s) esophagus. N Engl J Med 313:857–859 (1985).
7.
Cher ML, Bova GS, Moore DH, Small EJ, Carroll PR, et al: Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res 56:3091–3102 (1996).
8.
Cromer A, Carles A, Millon R, Ganguli G, Chalmel F, et al: Identification of genes associated with tumorigenesis and metastatic potential of hypopharyngeal cancer by microarray analysis. Oncogene 23:2484–2498 (2004).
9.
de Both NJ, Wijnhoven BP, Sleddens HF, Tilanus HW, Dinjens WN: Establishment of cell lines from adenocarcinomas of the esophagus and gastric cardia growing in vivo and in vitro. Virchows Arch 438:451–456 (2001).
10.
El-Rifai W, Frierson HF Jr, Moskaluk CA, Harper JC, Petroni GR, et al: Genetic differences between adenocarcinomas arising in Barrett’s esophagus and gastric mucosa. Gastroenterology 121:592–598 (2001).
11.
Frierson HF Jr, El-Naggar AK, Welsh JB, Sapinoso LM, Su AI, et al: Large scale molecular analysis identifies genes with altered expression in salivary adenoid cystic carcinoma. Am J Pathol 161:1315–1323 (2002).
12.
Garnis C, Coe BP, Ishkanian A, Zhang L, Rosin MP, Lam WL: Novel regions of amplification on 8q distinct from the MYC locus and frequently altered in oral dysplasia and cancer. Genes Chromosomes Cancer 39:93–98 (2004).
13.
Hughes SJ, Nambu Y, Soldes OS, Hamstra D, Rehemtulla A, et al: Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma. Cancer Res 57:5571–5578 (1997).
14.
Isola JJ, Kallioniemi OP, Chu LW, Fuqua SA, Hilsenbeck SG, et al: Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am J Pathol 147:905–911 (1995).
15.
Jain AN, Tokuyasu TA, Snijders AM, Segraves R, Albertson DG, Pinkel D: Fully automatic quantification of microarray image data. Genome Res 12:325–332 (2002).
16.
Lee YG, Macoska JA, Korenchuk S, Pienta KJ: MIM, a potential metastasis suppressor gene in bladder cancer. Neoplasia 4:291–294 (2002).
17.
Menke-Pluymers MB, Schoute NW, Mulder AH, Hop WC, van Blankenstein M, Tilanus HW: Outcome of surgical treatment of adenocarcinoma in Barrett’s oesophagus. Gut 33:1454–1458 (1992).
18.
Morales TG, Sampliner RE, Bhattacharyya A: Intestinal metaplasia of the gastric cardia. Am J Gastroenterol 92:414–418 (1997).
19.
Moskaluk CA, Hu J, Perlman EJ: Comparative genomic hybridization of esophageal and gastroesophageal adenocarcinomas shows consensus areas of DNA gain and loss. Genes Chromosomes Cancer 22:305–311 (1998).
20.
Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, et al: ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6:1–6 (2004).
21.
Riegman PH, Vissers KJ, Alers JC, Geelen E, Hop WC, et al: Genomic alterations in malignant transformation of Barrett’s esophagus. Cancer Res 61:3164–3170 (2001).
22.
Rockett JC, Larkin K, Darnton SJ, Morris AG, Matthews HR: Five newly established oesophageal carcinoma cell lines: phenotypic and immunological characterization. Br J Cancer 75:258–263 (1997).
23.
Sasisekharan R, Shriver Z, Venkataraman G, Narayanasami U: Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer 2:521–528 (2002).
24.
Shimada Y, Imamura M, Wagata T, Yamaguchi N, Tobe T: Characterization of 21 newly established esophageal cancer cell lines. Cancer 69:277–284 (1992).
25.
Snijders AM, Nowak N, Segraves R, Blackwood S, Brown N, et al: Assembly of microarrays for genome-wide measurement of DNA copy number. Nat Genet 29:263–264 (2001).
26.
Spechler SJ, Zeroogian JM, Antonioli DA, Wang HH, Goyal RK: Prevalence of metaplasia at the gastro-oesophageal junction. Lancet 344:1533–1536 (1994).
27.
Stiles BM, Bhargava A, Adusumilli PS, Stanziale SF, Kim TH, et al: The replication-competent oncolytic herpes simplex mutant virus NV1066 is effective in the treatment of esophageal cancer. Surgery 134:357–364 (2003).
28.
Stocks SC, Pratt N, Sales M, Johnston DA, Thompson AM, et al: Chromosomal imbalances in gastric and esophageal adenocarcinoma: specific comparative genomic hybridization-detected abnormalities segregate with junctional adenocarcinomas. Genes Chromosomes Cancer 32:50–58 (2001).
29.
Tan JM, Tock EP, Chow VT: The novel human C8ORF17 (C8orf17) gene exhibits tissue specific expression, maps to chromosome 8q24.2, and is overexpressed/amplified in high grade cancers of the breast and prostate. Mol Pathol 56:109–115 (2003).
30.
Tselepis C, Morris CD, Wakelin D, Hardy R, Perry I, et al: Upregulation of the oncogene c-myc in Barrett’s adenocarcinoma: induction of c-myc by acidified bile acid in vitro. Gut 52:174–180 (2003).
31.
van Dekken H, Geelen E, Dinjens WN, Wijnhoven BP, Tilanus HW, et al: Comparative genomic hybridization of cancer of the gastroesophageal junction: deletion of 14q31→q32.1 discriminates between esophageal (Barrett’s) and gastric cardia adenocarcinomas. Cancer Res 59:748–752 (1999).
32.
van Dekken H, Alers JC, Riegman PH, Rosenberg C, Tilanus HW, Vissers K: Molecular cytogenetic evaluation of gastric cardia adenocarcinoma and precursor lesions. Am J Pathol 158:1961–1967 (2001).
33.
van Dekken H, Wink JC, Vissers KJ, van Marion R, Koppert LB, et al: Genomic analysis of early adenocarcinoma of the esophagus or gastroesophageal junction: Tumor progression is associated with alteration of 1q and 8p sequences. Genes Chromosomes Cancer 45:516–525 (2006).
34.
van Duin M, van Marion R, Vissers K, Watson JE, van Weerden WM, et al: High-resolution array comparative genomic hybridization of chromosome arm 8q: evaluation of genetic progression markers for prostate cancer. Genes Chromosomes Cancer 44:438–449 (2005a).
35.
van Duin M, van Marion R, Watson JE, Paris PL, Lapuk A, et al: Construction and application of a full-coverage, high-resolution, human chromosome 8q genomic microarray for comparative genomic hybridization. Cytometry A 63:10–19 (2005b).
36.
Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, et al: Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3:RESEARCH0034 (2002).
37.
Walch AK, Zitzelsberger HF, Bink K, Hutzler P, Bruch J, et al: Molecular genetic changes in metastatic primary Barrett’s adenocarcinoma and related lymph node metastases: comparison with nonmetastatic Barrett’s adenocarcinoma. Mod Pathol 13:814–824 (2000).
38.
Watson JE, Doggett NA, Albertson DG, Andaya A, Chinnaiyan A, et al: Integration of high-resolution array comparative genomic hybridization analysis of chromosome 16q with expression array data refines common regions of loss at 16q23→qter and identifies underlying candidate tumor suppressor genes in prostate cancer. Oncogene 23:3487–3494 (2004).
39.
Wells DE, Hill A, Lin X, Ahn J, Brown N, Wagner MJ: Identification of novel mutations in the human EXT1 tumor suppressor gene. Hum Genet 99:612–615 (1997).
40.
Woodings JA, Sharp SJ, Machesky LM: MIM-B, a putative metastasis suppressor protein, binds to actin and to protein tyrosine phosphatase delta. Biochem J 371:463–471 (2003).
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.